These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32917533)

  • 1. Sustained Safety and Performance of the Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Pooled Outcomes of the BIOSOLVE-II and -III Trials at 3 Years.
    Haude M; Ince H; Kische S; Toelg R; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Barbato E; Garcia-Garcia HM; Waksman R
    Cardiovasc Revasc Med; 2020 Sep; 21(9):1150-1154. PubMed ID: 32917533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III.
    Haude M; Ince H; Kische S; Abizaid A; Tölg R; Alves Lemos P; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Barbato E; Garcia-Garcia HM; Waksman R;
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):E502-E511. PubMed ID: 30079472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years.
    Haude M; Toelg R; Lemos PA; Christiansen EH; Abizaid A; von Birgelen C; Neumann FJ; Wijns W; Ince H; Kaiser C; Lim ST; Escaned J; Eeckhout E; Garcia-Garcia HM; Waksman R
    Cardiovasc Revasc Med; 2022 May; 38():106-110. PubMed ID: 34364807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
    Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
    Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III.
    Haude M; Ince H; Kische S; Abizaid A; Tölg R; Alves Lemos P; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Wijns W; Garcia-Garcia HM; Waksman R
    EuroIntervention; 2017 Jul; 13(4):432-439. PubMed ID: 28504239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
    Haude M; Ince H; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Eeckhout E; Garcia-Garcia HM; Waksman R
    EuroIntervention; 2020 Feb; 15(15):e1375-e1382. PubMed ID: 30803936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
    Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Onuma Y; Garcia-Garcia HM; Waksman R
    Eur Heart J; 2016 Sep; 37(35):2701-9. PubMed ID: 27190094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
    Haude M; Erbel R; Erne P; Verheye S; Degen H; Vermeersch P; Weissman N; Prati F; Bruining N; Waksman R; Koolen J
    EuroIntervention; 2016 Jun; 12(2):e160-6. PubMed ID: 27290675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
    Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R
    Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry.
    Wlodarczak A; Montorsi P; Torzewski J; Bennett J; Starmer G; Buck T; Haude M; Moccetti M; Wiemer M; Lee MK; Verheye S
    EuroIntervention; 2023 Jun; 19(3):232-239. PubMed ID: 37226676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
    Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
    Haude M; Erbel R; Erne P; Verheye S; Degen H; Böse D; Vermeersch P; Wijnbergen I; Weissman N; Prati F; Waksman R; Koolen J
    Lancet; 2013 Mar; 381(9869):836-44. PubMed ID: 23332165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
    Xu K; Fu G; Xu B; Zhou Y; Su X; Liu H; Zhang Z; Yu B; Wang X; Han Y;
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):832-838. PubMed ID: 30888736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.
    Verheye S; Wlodarczak A; Montorsi P; Torzewski J; Bennett J; Haude M; Starmer G; Buck T; Wiemer M; Nuruddin AAB; Yan BP; Lee MK
    Catheter Cardiovasc Interv; 2021 Jul; 98(1):E1-E8. PubMed ID: 32881396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a biodegradable polymer Cobalt-Chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: A pooled analysis of the CREDIT II and CREDIT III trials.
    Wang G; Wang H; Xu B; Yang Y; Yang Z; Li H; Zhang Z; Wang H; Yang L; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):512-519. PubMed ID: 28112473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.